



International Hybrid workshop

Improve the chances of a successful pregnancy

11 November 2022

Brussels, Belgium

Contact: Chloe Xilinas – Senior Medical Education Manager

Email: chloe.xilinas@medeaacademy.com

Mobile: +39 3466277262

Address: Via Monte Napoleone 8 / 20121 Milan, Italy

Website: www.medeacademy.com

MeδEA
MeMedical Education Academy

Contents

DATE & VENUE	3
CHAIRS	3
OVERVIEW.....	4
LEARNING OBJECTIVES	4
TARGET AUDIENCE	4
ACCREDITATION	4
LANGUAGE.....	5
SCIENTIFIC PROGRAMME	5

DATE & VENUE

11 November 2023

Brussels, Belgium

CHAIRS

Carlo Alviggi

Federico II University

Naples, Italy

Christophe Blockeel

Centre for Reproductive Medicine

Universitair Ziekenhuis Brussel

Brussels, Belgium

Sandro C. Esteves

Androfert · Andrology and Human

Reproduction Clinic

Campinas, Brazil

Robert Fischer

Fertility Centre Hamburg

Hamburg, Germany

Peter Humaidan

Skive Regional Hospital and Faculty of Health

Aarhus University

Fertility Clinic

Skive, Denmark

FACULTY

Carlo Alviggi

Federico II University

Naples, Italy

Christophe Blockeel

Centre for Reproductive Medicine

Universitair Ziekenhuis Brussel

Brussels, Belgium

Robert Fischer

Fertility Centre Hamburg
Hamburg, Germany

Alberto Vaiarelli

Genera Roma
Centre for Reproductive Medicine
Rome, Italy

Hakan Yarali

Hacettepe University Anatolia IVF and Women's Health Center
Ankara, Turkey

OVERVIEW

This educational activity will focus on the main aspects of IVF. The program will start with the low prognosis patients, focusing on the diagnostic assessment of the condition; then, the lectures will be focused on the treatments, mainly ART, defining the clinical applicability in the real-world activity of the new Poseidon criteria for low prognosis patients.

The program took place in Asia Pacific and the next workshop in Europe and will engage renowned international and regional experts with vast clinical experience in constantly evolving subjects.

LEARNING OBJECTIVES

After attending the educational activities, learners will be able to:

- Define severe LH and FSH deficiency and patient management.
- Discuss and debate the management of low prognosis patients.
- Explain the role of Pharmacogenetics in COS and explore recurrent implantation failures.
- Comprehend the new low prognosis concept and its application in clinical practice.
- Individualize and manage women with expected or unexpected prognosis to ART as per the POSEIDON classification.
- Evaluate luteal phase supplementations in fresh and frozen cycles.
- Estimate pregnancy outcomes in the freeze-all strategy.

TARGET AUDIENCE

The program is intended for clinicians, embryologists, andrologists, scientists, and managers working in ART who wish to update their knowledge of advanced techniques and scientific innovations and understand best practices using evidence-based models of care.

ACCREDITATION

This program will be submitted for CME accreditation to EACCME® (European Accreditation Council for Continuing for Medical Education).

LANGUAGE

The official language of the activity will be English.

SCIENTIFIC PROGRAMME

11 November 2023

09.00 MedEA Welcome and introduction

Robert Fischer, Germany

09.05 Local welcome

Christophe Blockeel

09.10 Workshop introduction

Carlo Alviggi, Italy

09.15 L1 – Low prognosis patient’s introduction to the POSEIDON criteria

Robert Fischer, Germany

09.40 L2 -Management strategies in POSEIDON group 1 and 2 patients (LH FSH deficiency)

Carlo Alviggi, Italy

10.05 L3 - Management strategies in POSEIDON group 3 and 4 patients

Robert Fischer, Germany

10.30 Discussion

11.00 Coffee break

11.20 L4 – The role of pharmacogenetic in ART

Carlo Alviggi, Italy

11.45 L5 - Managing a good prognosis patient

Christophe Blockeel, Belgium

12.00 L6 – Duo Stim to Optimize Number of Oocytes and Time to pregnancy in Low Prognosis Patients

Alberto Vaiarelli

12.25 Discussion

13.00 Lunch

14.00 L7 –Luteal phase supplementations in fresh and frozen cycles

Alberto Vaiarelli

14.25 L8 – Recurrent implantation failure definition diagnosis and management

Hakan Yarali, Turkey

14.50 Discussion

15.10 Coffee break

15.30 L9 - Freeze all strategy - for all patients?

Christophe Blockeel, Belgium

15.55 Discussion

16.20 Closing remarks

Robert Fischer, Germany; Carlo Alviggi, Italy; Christophe Blockeel, Belgium